Ampliphi Biosciences Corp (APHB) 0.1850 $APHB
AmpliPhi Update: Key Highlights From The Shareholder Conference Call
Trevor Lowenthal - at Seeking Alpha - Tue Jan 06, 10:57AM CST
AmpliPhi Provides Shareholder Update
Business Wire - Mon Jan 05, 7:29PM CST
--2015 Uplisting to Major Exchange Expected
XON: 39.30 (+1.05)
AmpliPhi Bio to host shareholder update
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:28AM CST
AmpliPhi BioSciences to Host Shareholder Update Conference Call
Business Wire - Tue Dec 30, 6:11PM CST
AmpliPhi BioSciences Corporation (OTCQB:APHB) ("AmpliPhi"
, the leader in the discovery and development of bacteriophage based therapies to treat drug resistant bacterial infections, today announced that it will host a shareholder update conference call on Monday, January 05, 2015 at 4:15 PM ET.
XON: 39.30 (+1.05)
Intrexon Corporation Has Two Overlooked Opportunities In The Anti-Infective Space
Trevor Lowenthal - at Seeking Alpha - Mon Dec 29, 11:51AM CST
XON: 39.30 (+1.05), OGEN: 0.91 (+0.16)
Update: AmpliPhi Is Making Important Moves To Advance Its Anti-Infective Pipeline
Trevor Lowenthal - at Seeking Alpha - Fri Dec 26, 10:55PM CST
Acinetobacter Infections - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5pbmng/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AmpliPhi Biosciences - Melinta Therapeutics - Pfizer - Sarepta Therapeutics - Achaogen - Evolva - Novabiotics - Aridis Pharmaceuticals - FOB Synthesis - Synthetic Biologics - Trana Discovery - Cantab Biopharmaceuticals - Omnia Molecular - Northern Antibiotics - Nosopharm - Adenium Biotech - Vaxdyn For more information visit http://www.researchandmarkets.com/research/5p...netobacter
SYN: 2.13 (+0.18), SRPT: 12.76 (+0.11)
Update: AmpliPhi Q3 Earnings
Trevor Lowenthal - at Seeking Alpha - Wed Nov 19, 12:14AM CST
AmpliPhi reports departure of president and CEO Philip J. Young
M2 - Mon Sep 22, 6:24AM CDT
Bacteriophage therapies company AmpliPhi BioSciences (Other OTC:APHB) reported on Friday the resignation of Philip J. Young as its president and CEO effective 15 September.
AmpliPhi Announces Departure of CEO
Business Wire - Fri Sep 19, 7:00AM CDT
AmpliPhi BioSciences Corporation (OTC:APHB) ("AmpliPhi" , the leader in the discovery and development of bacteriophage based therapies to treat drug resistant bacterial infections, today announced that Philip J. Young has stepped down from his role as President and CEO. Mr Young's resignation was by mutual agreement with AmpliPhi's Board of Directors with his departure from the Company being effective Monday, September 15.
XON: 39.30 (+1.05)
AmpliPhi to Present at Rodman and Renshaw 16th Annual Global Investment Conference
Business Wire - Thu Sep 04, 6:00AM CDT
AmpliPhi BioSciences Corporation (OTCBB:APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that Philip Young, President and CEO, will present a corporate overview at the 16th Annual Global Investment Conference on Tuesday, September 09 at 2:30pm ET at the New York Palace Hotel in New York, NY.
XON: 39.30 (+1.05)
Retinal Degeneration - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3mjdx6/retinal) has announced the addition of the "Retinal Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Degeneration - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Degeneration and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Mentioned: - AmpliPhi Biosciences Corporation - SanBio, Inc. - to-BBB technologies BV - Aprogen, Inc. - X-BODY BioSciences, Inc. - GenSight Biologics - Spark Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/3mjdx6/retinal
AmpliPhi to Present at Upcoming Healthcare Conferences
Business Wire - Wed Feb 26, 6:30AM CST
AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34th Annual Healthcare Conference at the Boston Marriott Copley Place Hotel in Boston at 2:50 pm EST (11:50 am PST) on Monday, March 3, 2014.
FSLR: 48.84 (-0.58)
AmpliPhi Update: Key Highlights From The Shareholder Conference Call
Trevor Lowenthal - at Seeking Alpha - Tue Jan 06, 10:57AM CST
AmpliPhi Provides Shareholder Update
Business Wire - Mon Jan 05, 7:29PM CST
--2015 Uplisting to Major Exchange Expected
XON: 39.30 (+1.05)
AmpliPhi Bio to host shareholder update
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:28AM CST
AmpliPhi BioSciences to Host Shareholder Update Conference Call
Business Wire - Tue Dec 30, 6:11PM CST
AmpliPhi BioSciences Corporation (OTCQB:APHB) ("AmpliPhi"
, the leader in the discovery and development of bacteriophage based therapies to treat drug resistant bacterial infections, today announced that it will host a shareholder update conference call on Monday, January 05, 2015 at 4:15 PM ET. XON: 39.30 (+1.05)
Intrexon Corporation Has Two Overlooked Opportunities In The Anti-Infective Space
Trevor Lowenthal - at Seeking Alpha - Mon Dec 29, 11:51AM CST
XON: 39.30 (+1.05), OGEN: 0.91 (+0.16)
Update: AmpliPhi Is Making Important Moves To Advance Its Anti-Infective Pipeline
Trevor Lowenthal - at Seeking Alpha - Fri Dec 26, 10:55PM CST
Acinetobacter Infections - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5pbmng/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AmpliPhi Biosciences - Melinta Therapeutics - Pfizer - Sarepta Therapeutics - Achaogen - Evolva - Novabiotics - Aridis Pharmaceuticals - FOB Synthesis - Synthetic Biologics - Trana Discovery - Cantab Biopharmaceuticals - Omnia Molecular - Northern Antibiotics - Nosopharm - Adenium Biotech - Vaxdyn For more information visit http://www.researchandmarkets.com/research/5p...netobacter
SYN: 2.13 (+0.18), SRPT: 12.76 (+0.11)
Update: AmpliPhi Q3 Earnings
Trevor Lowenthal - at Seeking Alpha - Wed Nov 19, 12:14AM CST
AmpliPhi reports departure of president and CEO Philip J. Young
M2 - Mon Sep 22, 6:24AM CDT
Bacteriophage therapies company AmpliPhi BioSciences (Other OTC:APHB) reported on Friday the resignation of Philip J. Young as its president and CEO effective 15 September.
AmpliPhi Announces Departure of CEO
Business Wire - Fri Sep 19, 7:00AM CDT
AmpliPhi BioSciences Corporation (OTC:APHB) ("AmpliPhi"
, the leader in the discovery and development of bacteriophage based therapies to treat drug resistant bacterial infections, today announced that Philip J. Young has stepped down from his role as President and CEO. Mr Young's resignation was by mutual agreement with AmpliPhi's Board of Directors with his departure from the Company being effective Monday, September 15. XON: 39.30 (+1.05)
AmpliPhi to Present at Rodman and Renshaw 16th Annual Global Investment Conference
Business Wire - Thu Sep 04, 6:00AM CDT
AmpliPhi BioSciences Corporation (OTCBB:APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that Philip Young, President and CEO, will present a corporate overview at the 16th Annual Global Investment Conference on Tuesday, September 09 at 2:30pm ET at the New York Palace Hotel in New York, NY.
XON: 39.30 (+1.05)
Retinal Degeneration - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3mjdx6/retinal) has announced the addition of the "Retinal Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Degeneration - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Degeneration and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Mentioned: - AmpliPhi Biosciences Corporation - SanBio, Inc. - to-BBB technologies BV - Aprogen, Inc. - X-BODY BioSciences, Inc. - GenSight Biologics - Spark Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/3mjdx6/retinal
AmpliPhi to Present at Upcoming Healthcare Conferences
Business Wire - Wed Feb 26, 6:30AM CST
AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34th Annual Healthcare Conference at the Boston Marriott Copley Place Hotel in Boston at 2:50 pm EST (11:50 am PST) on Monday, March 3, 2014.
FSLR: 48.84 (-0.58)
